Annovis Bio Inc. (NYSE: ANVS) Highlights Buntanetap Results At 17Th Clinical Trials On Alzheimer's Disease ('CTAD') 2024 Conference

Date

11/5/2024 11:07:05 PM

(MENAFN- Investor Brand Network)

Two posters were presented by Annovis' President and CEO, Dr. Maria Maccecchini, focusing on the company's lead drug candidate buntanetap and its performance in clinical trials for the treatment of Alzheimer's disease (“AD”).
A leading event for the Alzheimer's research community, CTAD 2024, brought together key members of Pharmaceutical companies, academic research centers, and patient advocacy groups to discuss avenues for AD treatment.
Buntanetap has been shown to significantly improve cognition in early AD patients, both ApoE4 carriers and non-carriers, and normalize biomarkers associated with AD pathology.
The company is preparing for Phase 3 clinical trials for buntanetap in early-stage Alzheimer's patients: a 6-month study to confirm symptomatic benefits and an 18-month study to explore disease-modifying effects.

Annovis (NYSE: ANVS) , a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (“AD”) and Parkinson's disease (“PD”), presented two scientific posters at the 17th Clinical Trials on Alzheimer's Disease (“CTAD”) conference ( ), held between Oct. 29 and Nov. 1 in Marid, Spain.

The posters are now available online on Annovis'...

NOTE TO INVESTORS:
The latest news and updates relating to ANVS are available in the company's newsroom at

About BioMedWire

BioMedWire
(“BMW”) is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 70+ brands within the
Dynamic Brand Portfolio
@
IBN
that delivers :
(1) access to a vast network of wire solutions via
InvestorWire
to efficiently and effectively reach a myriad of target markets, demographics and diverse industries ;
(2) article and
editorial syndication to 5,000+ outlets ;
(3) enhanced
press release enhancement
to ensure maximum impact ;
(4)
social media distribution
via IBN to millions of social media followers ;
and (5) a full array of tailored
corporate communications solutions . With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today's market, BMW brings its clients unparalleled recognition and brand awareness.

BMW is where breaking news, insightful content and actionable information converge.

To receive SMS alerts from BioMedWire,“Biotech” to 888-902-4192 (U.S. Mobile Phones Only)

For more information, please visit

Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published:
/Disclaimer

BioMedWire
San Francisco, CA

415.949.5050 Office
[email protected]

BioMedWire is powered by
IBN

MENAFN05112024000224011066ID1108855061

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.